Partnership to Market Clinical Data Analyses

A strategic alliance has been announced that will market clinical data analyses to aid molecular and clinical research efforts in developing new therapies for patients with cardiovascular diseases. AnVil, Inc. (Burlington, MA, USA) will partner with Genomics Collaborative, Inc. (GCI, Cambridge, MA, USA) in this alliance.

The agreement calls for AnVil to work with GCI in analyzing cardiovascular clinical data from GCI's Global Repository, a proprietary database of properly consented, well-
annotated DNA, tissue, and serum samples collected from more than 115,000 individuals. Both companies will leverage the knowledge gained from these analyses by marketing the results to pharmaceutical, biotechnology, and clinical research organizations (CROs) with the objective of facilitating new technological advances for treating patients with cardiovascular diseases.

"GCI's comprehensive databases are a fertile hunting ground for new predictive and treatment models, and we're confident our work will result in high-quality and high-value R&D resources for pharmaceutical and biotechnology companies and CROs,” said Dr. Richard Gill, president and CEO of AnVil.

AnVil will use its domain expertise in life sciences and medicine, along with its analytical and visualization technologies and services, to survey and evaluate GCI's databases related to the initial stages of coronary artery disease, myocardial infarction, hyperlipidemia and hypertension. The analyses and hypotheses developed in this phase will be used to build predictive and analytical models of specified patient populations and treatment characteristics.




Related Links:
AnVil
Genomics Collaborative